EPB41L4A-AS1 and COVID-19: The consistent upregulation of EAS1 across multiple coronavirus genera (including SARS-CoV, MERS-CoV, and HCoV-229E) suggests that this mechanism is not unique to SARS-CoV-2 and may therefore represent a potential host-directed target worthy of investigation for mitigating organ injury in COVID-19 and, potentially, in diseases caused by other coronaviruses.